Alphatec Hlds (ATEC) Stock Forecast & Price Target

Alphatec Holdings is a company that has shown strong growth and potential in the spinal surgery market, with a core business that remains strong and a trajectory of continued growth. Despite some challenges in their EOS business, the company has reported strong revenue growth, case volume increase, and new user additions. Additionally, with new product offerings and growth potential in Japan, Alphatec has the potential to stand out among its competitors. While there may be some near-term weakness due to execution issues, the company is making efforts to address them and the pullback in the stock is viewed as overdone. This analysis is based on the company's Q1 results, which showed a strong gross margin and revenue growth, beating consensus estimates for operating margin and EBITDA margin. Despite a lower guidance for total revenue due to challenges in the EOS business, Alphatec's core business remains intact and the company is making progress on profitability. With the stock trading at a reduced price and a multiple compression across small cap MedTech, this presents an opportunity for investors to purchase the stock at a lower price point, making Alphatec Holdings a promising investment.

Alphatec Holdings is facing multiple challenges, including poor sales execution and decreased revenue from the EOS imaging business, leading to a topline miss and a lowered revenue guidance for 2026. The company expects to maintain profitability, but there are risks such as commercial, partnership, regulatory, financial, and intellectual property challenges. Based on an EV-to-sales multiple analysis and discounted cash flow method, the financial analysis projects a 12-month price target of $24.00; however, potential risks to this analysis must be considered, such as the company's reliance on the EOS installed base and competition in the spine market. Finally, on the recent earnings call, management noted a decline in EOS growth, challenges with coordinating installations, and a decline in revenue per case, causing a slight decrease in average selling prices, though management expects steady ASPs for the year and solid margin performance.